Targeted therapies in hepatocellular carcinoma: past, present, and future

Area of Science:

• Oncology
• Pharmacology

Background:

• Targeted therapies are crucial for advanced, unresectable, or metastatic hepatocellular carcinoma (HCC).
• Previous targeted agents focusing on c-Met, TGF-β, and FGFR showed limited clinical benefit in HCC.
• Despite past setbacks, these targets remain relevant for future therapeutic development.

Purpose of the Study:

• To review previously evaluated therapeutic targets in HCC.
• To explore novel and emerging targets for HCC treatment.
• To assess the continued relevance of these targets in ongoing and future HCC studies.

Main Methods:

• Literature review of clinical studies on targeted therapies for HCC.
• Analysis of previously evaluated targets (c-Met, TGF-β, FGFR).
• Identification and discussion of novel targets (Wnt/β-catenin, c-Myc, GPC3, PPT1).

Main Results:

• Several targeted therapies for HCC have been investigated.
• Past targets like c-Met, TGF-β, and FGFR did not demonstrate significant clinical benefit.
• Novel targets including the Wnt/β-catenin pathway, c-Myc, GPC3, and PPT1 are under active investigation.

Conclusions:

• While past targeted therapies for HCC yielded limited success, the identified targets remain important.
• Novel targets show promise for future HCC treatment strategies.
• Continued research into these targets is essential for advancing HCC therapy.